Developer docs
API playgroundTry for free, no card

Search company profiles

Parkwalk Advisors

Full company profile

uuid00000rj

Namestring
Parkwalk Advisors
Legal namestring
Parkwalk Advisors Ltd
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Parkwalk Advisors Ltd is a London-based venture capital and investment management firm founded in 2009 that specialises in backing deep technology companies spun out of UK universities and research institutions. Operating as a wholly-owned subsidiary of IP Group plc, the firm manages Enterprise Investment Scheme (EIS) funds that provide tax-efficient investment vehicles for UK-resident investors while channeling capital into spinouts across sectors including AI, quantum computing, hardware, materials, cleantech, digital health, life sciences, medtech, and agtech. As of April 2026, Parkwalk reported having backed over 200 companies and raising more than £1 billion in cumulative funding across its portfolio, and Beauhurst ranked it the UK's most active investor in university spinouts in 2025.

Parkwalk invests across the spinout lifecycle from pre-seed to scale, almost always as a participating or co-leading investor alongside institutional partners such as Oxford Science Enterprises, Cambridge Enterprise Ventures, UK Innovation and Science Seed Fund (UKI2S), Northern Gritstone, and the Development Bank of Wales. The firm's deal flow is sourced through embedded relationships with major UK universities and their technology transfer offices (Oxford, Cambridge, UCL, Manchester, and the National Physical Laboratory), giving it preferential access to academic IP at the point of commercialisation. Recent notable investments include Quantum Motion ($160M Series C, 2026), Brainomix (AI medical imaging, £18.8M Series C, 2026), Phasecraft ($34M Series B quantum software, 2025), and Scripta Therapeutics ($12M AI/biology seed, 2025). The firm is regulated by the UK Financial Conduct Authority (FRN: 502237) and is registered in England and Wales at 3 Pancras Square, King's Cross.

The business model is fund management: Parkwalk generates revenue through management fees on EIS-registered fund vintages and carried interest on successful exits, with its offerings explicitly restricted to UK residents. Distribution is direct to high-net-worth and sophisticated investors via the firm's investor relations team, with co-investment opportunities available for direct stakes in individual portfolio companies. The firm employs 11-50 staff organised around investment, business development, sales/marketing, finance, and legal functions. Strategic positioning emphasises specialist origination in UK academic spinouts rather than competing head-on with generalist VCs, with the value proposition to LPs anchored in EIS tax relief plus exposure to deeptech companies at the seed-to-scale boundary.

Short descriptiontext

Parkwalk Advisors is a London-based VC firm that invests in deeptech spinouts from UK universities across AI, quantum, healthtech, and cleantech. Part of IP Group plc, it manages EIS funds for UK investors and has backed over 200 portfolio companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, university spinout funding, EIS fund management, deeptech seed investing, UK technology transfer
Industry2 codes
PRIMARYFSAHAKAI
Emerging Managers / Seeding Platforms
Financial & Insurance/Hedge Funds & Alternative Investments/Alternative Investments — Fund of Funds & Multi-Manager Platforms
SECONDARYBPAHAOAE
Equity Capital Advisory (Private Equity Placements, Growth Capital)
NAICS code3 codes
  • Portfolio Management and Investment Advice52394
  • All Other Financial Investment Activities52399
  • Other Financial Vehicles52599
SIC code2 codes
  • Investment Advice6282
  • Finance Services6199
Product category
Venture Capital and Private Equity (University Spinout Investment)
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Parkwalk Advisors is an FCA-regulated investment management firm that raises and deploys capital through Enterprise Investment Scheme (EIS) funds into early-stage UK university spinouts developing deeptech in AI, quantum computing, hardware, materials, digital health, life sciences, medtech, agtech and cleantech. The firm invests across the spinout lifecycle from seed to scale and additionally offers co-investment opportunities for investors wanting direct stakes in individual portfolio companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Parkwalk Advisors is a venture capital and investment management firm, not a product/technology company. It operates as an EIS (Enterprise Investment Scheme) fund manager that invests in UK university spinouts across deeptech sectors including AI, Quantum Computing, Hardware, Cleantech, Digital Health, and Life Sciences. The firm provides funding, expertise, and networks to help convert academic research into commercial innovations. The company manages investment funds and offers tax-efficient investment opportunities to investors, functioning as a fund manager rather than a product or service provider to end customers.

Product and service2 records
1EIS Investment Funds
CategoryEIS Fund Management
Description

Tax-efficient Enterprise Investment Scheme (EIS) fund products for UK resident investors seeking exposure to UK university spinouts, offering capital gains tax relief, income tax relief and inheritance tax planning benefits. Parkwalk has been recognised as Best EIS Investment Manager at the Growth Investor Awards 2025.

2Co-Investment Opportunities
CategoryCo-Investment Opportunities
Description

Direct co-investment opportunities for qualified investors wanting to take direct stakes in individual UK university spinout portfolio companies alongside Parkwalk's EIS fund investments. Available globally per Parkwalk's distribution scope and structured alongside co-investment partners such as Oxford Science Enterprises, Cambridge Enterprise, Northern Gritstone and UKI2S.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1UK Universities (Oxford, Cambridge, UCL, Manchester, etc.)
Strategic tierCoreTypeOthers
Description

Parkwalk has established relationships with major UK universities including Oxford, Cambridge, UCL, Manchester, and others to source deeptech spinout investment opportunities. The firm bridges the gap between academic innovation and commercial success.

parkwalk.vc
Strategic tierCoreTypeOthers
Description

Oxford's technology transfer company that supports spinouts from the University of Oxford. Supported Scripta Therapeutics alongside Parkwalk and other investors.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based EIS and SEIS fund manager with a focus on life sciences, technology, and renewable energy. Competes with Parkwalk for EIS-eligible UK deeptech and life sciences investments from UK HNW investors.

TypeDirect peer
Description

UK EIS and SEIS fund manager focused on technology and growth-stage companies. Directly competes with Parkwalk in the UK EIS fund management market, serving similar HNW investor segments.

TypeDirect peer
Description

UK early-stage VC firm investing across technology and life sciences, with a strong EIS-fund offering. Co-invested alongside Parkwalk in Scripta Therapeutics and Phasecraft, directly competing for similar UK deeptech deal flow.

TypeDirect peer
Description

London-based EIS and VCT fund manager investing in UK growth companies including technology and life sciences. Competes with Parkwalk for EIS capital from UK HNW investors targeting tax-efficient deeptech exposure.

TypeBroad incumbent
Description

One of the largest UK VCs managing multiple EIS and SEIS fund products alongside growth-stage investments. A broader incumbent in the UK VC market that overlaps with Parkwalk in early-stage EIS-backed deeptech deals but operates at significantly larger scale.

TypeDirect peer
Description

University of Manchester and northern UK universities' investment vehicle targeting deeptech spinouts. Co-invested with Parkwalk in Cytotrait, competing for northern UK university spinout deal flow.

TypeDirect peer
Description

A public-private seed fund focused on UK deeptech and university spinouts. Co-leads rounds with Parkwalk (e.g., K3 Metrology, Ikarovec), making it both a competitor and frequent co-investment partner for early-stage UK spinout deals.

TypeRegional player
Description

UK regional VC and fund manager with VCT and EIS products across the UK regions. Operates in similar UK EIS/VCT fund management space but with a stronger regional SME focus rather than university spinouts.

TypeDirect peer
Description

Oxford University's affiliated investment fund ($1.1B AUM) that invests in Oxford spinouts across deeptech and life sciences. Directly competes with Parkwalk for the same UK university spinout deal flow and co-invests with Parkwalk in companies like Quantum Motion, Brainomix, Scripta Therapeutics, and Densix.

10Cambridge Enterprise Ventures
TypeDirect peer
Description

University of Cambridge's technology transfer and investment arm that invests in Cambridge spinouts. Co-invests with Parkwalk in xWatts, Trismik, and Xen Quantum, directly competing for the same Cambridge-origin deeptech deals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment354 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Parkwalk Advisors

Venture Capital and Private Equity (University Spinout Investment)parkwalkadvisors.com

Parkwalk Advisors is a London-based VC firm that invests in deeptech spinouts from UK universities across AI, quantum, healthtech, and cleantech. Part of IP Group plc, it manages EIS funds for UK investors and has backed over 200 portfolio companies.

What Parkwalk Advisors does

Parkwalk Advisors Ltd is a London-based venture capital and investment management firm founded in 2009 that specialises in backing deep technology companies spun out of UK universities and research institutions. Operating as a wholly-owned subsidiary of IP Group plc, the firm manages Enterprise Investment Scheme (EIS) funds that provide tax-efficient investment vehicles for UK-resident investors while channeling capital into spinouts across sectors including AI, quantum computing, hardware, materials, cleantech, digital health, life sciences, medtech, and agtech. As of April 2026, Parkwalk reported having backed over 200 companies and raising more than £1 billion in cumulative funding across its portfolio, and Beauhurst ranked it the UK's most active investor in university spinouts in 2025.

Parkwalk invests across the spinout lifecycle from pre-seed to scale, almost always as a participating or co-leading investor alongside institutional partners such as Oxford Science Enterprises, Cambridge Enterprise Ventures, UK Innovation and Science Seed Fund (UKI2S), Northern Gritstone, and the Development Bank of Wales. The firm's deal flow is sourced through embedded relationships with major UK universities and their technology transfer offices (Oxford, Cambridge, UCL, Manchester, and the National Physical Laboratory), giving it preferential access to academic IP at the point of commercialisation. Recent notable investments include Quantum Motion ($160M Series C, 2026), Brainomix (AI medical imaging, £18.8M Series C, 2026), Phasecraft ($34M Series B quantum software, 2025), and Scripta Therapeutics ($12M AI/biology seed, 2025). The firm is regulated by the UK Financial Conduct Authority (FRN: 502237) and is registered in England and Wales at 3 Pancras Square, King's Cross.

The business model is fund management: Parkwalk generates revenue through management fees on EIS-registered fund vintages and carried interest on successful exits, with its offerings explicitly restricted to UK residents. Distribution is direct to high-net-worth and sophisticated investors via the firm's investor relations team, with co-investment opportunities available for direct stakes in individual portfolio companies. The firm employs 11-50 staff organised around investment, business development, sales/marketing, finance, and legal functions. Strategic positioning emphasises specialist origination in UK academic spinouts rather than competing head-on with generalist VCs, with the value proposition to LPs anchored in EIS tax relief plus exposure to deeptech companies at the seed-to-scale boundary.

Parkwalk Advisors firmographics

Firmographics
Name
Parkwalk Advisors
Legal name
Parkwalk Advisors Ltd
Website
https://parkwalkadvisors.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Parkwalk Advisors is a London-based VC firm that invests in deeptech spinouts from UK universities across AI, quantum, healthtech, and cleantech. Part of IP Group plc, it manages EIS funds for UK investors and has backed over 200 portfolio companies.
Ownership category
akta.pro rank

Parkwalk Advisors industry classification

Industry
Product category
Venture Capital and Private Equity (University Spinout Investment)
NAICS
Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399), Other Financial Vehicles (52599)
SIC
Investment Advice (6282), Finance Services (6199)
akta.pro industry
PRIMARYFSAHAKAI
Emerging Managers / Seeding Platforms
Financial & Insurance/Hedge Funds & Alternative Investments/Alternative Investments — Fund of Funds & Multi-Manager Platforms
SECONDARYBPAHAOAE
Equity Capital Advisory (Private Equity Placements, Growth Capital)

Keywords

  • Venture capital investing
  • University spinout funding
  • EIS fund management
  • Deeptech seed investing
  • UK technology transfer

Where Parkwalk Advisors is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Parkwalk Advisors business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Distribution channels3 records

Marketing channels3 records

Parkwalk Advisors product offering

Product offering

Core offering

Parkwalk Advisors is an FCA-regulated investment management firm that raises and deploys capital through Enterprise Investment Scheme (EIS) funds into early-stage UK university spinouts developing deeptech in AI, quantum computing, hardware, materials, digital health, life sciences, medtech, agtech and cleantech. The firm invests across the spinout lifecycle from seed to scale and additionally offers co-investment opportunities for investors wanting direct stakes in individual portfolio companies.

Product overview

Parkwalk Advisors is a venture capital and investment management firm, not a product/technology company. It operates as an EIS (Enterprise Investment Scheme) fund manager that invests in UK university spinouts across deeptech sectors including AI, Quantum Computing, Hardware, Cleantech, Digital Health, and Life Sciences. The firm provides funding, expertise, and networks to help convert academic research into commercial innovations. The company manages investment funds and offers tax-efficient investment opportunities to investors, functioning as a fund manager rather than a product or service provider to end customers.

Differentiator

Problem solved

Functional benefit

Products and services

  • EIS Investment Funds Tax-efficient Enterprise Investment Scheme (EIS) fund products for UK resident investors seeking exposure to UK university spinouts, offering capital gains tax relief, income tax relief and inheritance tax planning benefits. Parkwalk has been recognised as Best EIS Investment Manager at the Growth Investor Awards 2025.
  • Co-Investment Opportunities Direct co-investment opportunities for qualified investors wanting to take direct stakes in individual UK university spinout portfolio companies alongside Parkwalk's EIS fund investments. Available globally per Parkwalk's distribution scope and structured alongside co-investment partners such as Oxford Science Enterprises, Cambridge Enterprise, Northern Gritstone and UKI2S.

Companies that use Parkwalk Advisors

Customer profile

Segments2 records

Ideal customer profiles2 records

Parkwalk Advisors technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Parkwalk Advisors partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • UK Universities (Oxford, Cambridge, UCL, Manchester, etc.)coreOthersParkwalk has established relationships with major UK universities including Oxford, Cambridge, UCL, Manchester, and others to source deeptech spinout investment opportunities. The firm bridges the gap between academic innovation and commercial success.
  • Oxford University InnovationcoreOthersOxford's technology transfer company that supports spinouts from the University of Oxford. Supported Scripta Therapeutics alongside Parkwalk and other investors.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Parkwalk Advisors competitors and assessment

Company assessment

Direct peers

  • Deepbridge Capital: UK-based EIS and SEIS fund manager with a focus on life sciences, technology, and renewable energy. Competes with Parkwalk for EIS-eligible UK deeptech and life sciences investments from UK HNW investors.
  • Oxford Capital: UK EIS and SEIS fund manager focused on technology and growth-stage companies. Directly competes with Parkwalk in the UK EIS fund management market, serving similar HNW investor segments.
  • AlbionVC: UK early-stage VC firm investing across technology and life sciences, with a strong EIS-fund offering. Co-invested alongside Parkwalk in Scripta Therapeutics and Phasecraft, directly competing for similar UK deeptech deal flow.
  • Calculus Capital: London-based EIS and VCT fund manager investing in UK growth companies including technology and life sciences. Competes with Parkwalk for EIS capital from UK HNW investors targeting tax-efficient deeptech exposure.
  • Northern Gritstone: University of Manchester and northern UK universities' investment vehicle targeting deeptech spinouts. Co-invested with Parkwalk in Cytotrait, competing for northern UK university spinout deal flow.
  • UK Innovation & Science Seed Fund (UKI2S): A public-private seed fund focused on UK deeptech and university spinouts. Co-leads rounds with Parkwalk (e.g., K3 Metrology, Ikarovec), making it both a competitor and frequent co-investment partner for early-stage UK spinout deals.
  • Oxford Science Enterprises: Oxford University's affiliated investment fund ($1.1B AUM) that invests in Oxford spinouts across deeptech and life sciences. Directly competes with Parkwalk for the same UK university spinout deal flow and co-invests with Parkwalk in companies like Quantum Motion, Brainomix, Scripta Therapeutics, and Densix.
  • Cambridge Enterprise Ventures: University of Cambridge's technology transfer and investment arm that invests in Cambridge spinouts. Co-invests with Parkwalk in xWatts, Trismik, and Xen Quantum, directly competing for the same Cambridge-origin deeptech deals.

Broad incumbents

  • Octopus Ventures: One of the largest UK VCs managing multiple EIS and SEIS fund products alongside growth-stage investments. A broader incumbent in the UK VC market that overlaps with Parkwalk in early-stage EIS-backed deeptech deals but operates at significantly larger scale.

Regional players

  • Maven Capital Partners: UK regional VC and fund manager with VCT and EIS products across the UK regions. Operates in similar UK EIS/VCT fund management space but with a stronger regional SME focus rather than university spinouts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Parkwalk Advisors social profiles

Digital presence

Parkwalk Advisors compliance and trust

Trust signal

Compliance1 record

Parkwalk Advisors financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Parkwalk Advisors leadership team

Management profile

Number of profiles

Profiles13 records

Parkwalk Advisors funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Parkwalk Advisors M&A and investment

M&A and investment

M&A

Investments354 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parkwalk Advisors

What does Parkwalk Advisors do?

Parkwalk Advisors is an FCA-regulated investment management firm that raises and deploys capital through Enterprise Investment Scheme (EIS) funds into early-stage UK university spinouts developing deeptech in AI, quantum computing, hardware, materials, digital health, life sciences, medtech, agtech and cleantech. The firm invests across the spinout lifecycle from seed to scale and additionally offers co-investment opportunities for investors wanting direct stakes in individual portfolio companies.

Is Parkwalk Advisors a public or private company?

Parkwalk Advisors is a private company. It is classified as corporate owned and is currently operating.

When was Parkwalk Advisors founded?

Parkwalk Advisors was founded in 2009. It employs 11 to 50 people.

Where is Parkwalk Advisors based?

Parkwalk Advisors is headquartered in London, United Kingdom, in the Europe region.

Who are Parkwalk Advisors's main competitors?

Direct peers on record are Deepbridge Capital, Oxford Capital, AlbionVC, Calculus Capital, Northern Gritstone, UK Innovation & Science Seed Fund (UKI2S), Oxford Science Enterprises and Cambridge Enterprise Ventures. Octopus Ventures is listed as a broad incumbent. Maven Capital Partners is listed as a regional player.

Does Parkwalk Advisors have an API?

No public API is recorded for Parkwalk Advisors.

What industry is Parkwalk Advisors in?

Parkwalk Advisors's product category is Venture Capital and Private Equity (University Spinout Investment). Its primary akta.pro industry code is FSAHAKAI, Emerging Managers / Seeding Platforms, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingParkwalk-backed Mind Foundry shifts focus to defence and national securityMind Foundry, a Parkwalk-backed company, has narrowed its focus to defense and national security, following CEO Lindsay Chadwick's appointment in late 2025. Parkwalk invested in the firm at founding and in its 2020 Series A. The shift aligns with Britain's £298 billion defense investment plan over four years.InsidermediaLeeds AI spinout raises £10m in Series A funding - will assess medical device performance in virtual patients before they reach real onesadsilico, a University of Leeds spinout, raised £10m in Series A funding to expand its AI and simulation technology for medical device testing. The round, backed by PXN Ventures, Northern Gritstone, and Parkwalk, will grow its team from 14 to 34. The company plans to use virtual patients to assess device performance before real trials.The future of tradingUK Spinout Investment Rises 38.2% to £1.56 Billion in H1 2026, Parkwalk ReportsUK university spinout investment reached £1.56 billion in H1 2026, up 38.2% from H2 2025, according to Parkwalk's annual report. First-time equity funding fell 68.3% to £47 million, while later-stage investment hit £760 million, its highest half-year total since 2021. International investors accounted for 86.1% of investment, the highest share this decade.StartupmagMoa Technology raises £22.2m co led by Oxford Science Enterprises and Supernova InvestMoa Technology raised £22.2m in a Series C round co-led by Oxford Science Enterprises and Supernova Invest. The funding will advance three late-stage herbicide programmes and its Moa Amplifiers, which reduce herbicide use. The company has over 80 novel modes of action and collaborations with Nufarm, Gowan, Certis, and Corteva.PR NewswireMoa Technology raises Series C round co-led by Oxford Science Enterprises and Supernova InvestMoa Technology raised a £22.2 million Series C round co-led by Oxford Science Enterprises and Supernova Invest. The funding will advance its three most advanced herbicide programmes and develop Moa Amplifiers, with over 80 novel mode of action areas discovered. The company expects to continue signing commercial research partnerships.NewswireMoa Technology raises Series C round co-led by Oxford Science Enterprises and Supernova InvestMoa Technology raised a £22.2 million Series C round co-led by Oxford Science Enterprises and Supernova Invest. The funding will advance its three most advanced herbicide programmes and the Moa Amplifiers programme, with over 80 novel mode of action areas discovered. The company expects to continue signing commercial research partnerships.StartupmagAI startup Mach42 closes £7m pre-seed led by IP Group with BGFMach42, an AI startup, closed a £7m pre-seed round led by IP Group with BGF to accelerate agentic-ready simulation for analog semiconductor verification. The funding will expand engineering and business development teams and drive commercial adoption of its machine-learning circuit-simulation models. The company targets power management devices, aiming to increase verification coverage by up to 100x.StartupmagGreentech startup Pixel-Flo raises £5.3m led by Northern Gritstone with SCVCPixel-Flo, a University of Sheffield spinout, raised £5.3m in seed funding led by Northern Gritstone and SCVC to industrialize its Continuous-Flow Mass Transfer system for microLED manufacturing. The company aims to address a production bottleneck and lower costs for microLED displays, with plans to expand its team and relocate.VestbeePixel-Flo raises £5.25M to solve the critical bottleneck in MicroLED manufacturingPixel-Flo, a Sheffield-based microLED manufacturing firm, raised £5.25M in seed funding from Northern Gritstone, SCVC, Parkwalk, and HTGF. The company's Continuous-Flo technology suspends microLED chips in liquid for assembly, aiming to scale production. The funding will support transition to industrial-scale production and customer evaluation.VestbeeTop European funding rounds closed in May 2026European startups closed funding rounds in May 2026, including Cytospire Therapeutics' £61M Series A and eleQtron's €57M Series A. The rounds span immuno-oncology, quantum computing, AI, and biotech, with capital used for clinical trials, scaling, and expansion.